Search
for
Sort by
Research 151–180 of 172
- Female pattern alopecia: current perspectives
- Anticancer agents against malaria: time to revisit?
- The investigation and management of hirsutism
- Polycystic ovary syndrome (PCOS) trilogy: a translational and clinical review
- Dermatological aspects of gender affirming medical treatment in transgender and gender diverse people: A systematic review
- Androgens/Androgen Receptor in the Management of Skin Diseases
- Capryloyl glycine and soy isoflavonoids in hypertrichosis: An experimental and placebo‐controlled clinical study
- Recent Approaches in the Treatment of Polycystic Ovary Syndrome: An Update
- Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
- Regenerative Capacity of Adipose Derived Stem Cells (ADSCs), Comparison with Mesenchymal Stem Cells (MSCs)
- Ethosomes: New Prospects in Transdermal Delivery
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Hyperandrogenic Disorders
- Evolution of hard proteins in the sauropsid integument in relation to the cornification of skin derivatives in amniotes
- Back to the Roots—An Overview of the Chemical Composition and Bioactivity of Selected Root-Essential Oils
- Extra-Intestinal Manifestation of Celiac Disease in Children
- Male infertility and genitourinary birth defects: there is more than meets the eye
- Associations between clinical data, vaccination status, antibody responses, and post-COVID-19 symptoms in Thais infected with SARS-CoV-2 Delta and Omicron variants: a 1-year follow-up study
- Emerging concepts: regenerative medicine in dermatology
- Development of Alginate/Carboxymethylcellulose Films Incorporated with <i>Canavalia ensiformis</i> Lectin (ConA) with Angiogenic Properties
- Stem-cell therapy in dermatology – Challenges and opportunities
- The Need and Management of hormone Imbalances in Women
- Free Testosterone Levels in Patients with Covid-19 and its Association with Disease Severity
- Vaniqa--eflornithine 13.9% cream.
- Human Dermal Safety Studies with Eflornithine HCl 13.9% Cream (Vaniqa™), a Novel Treatment for Excessive Facial Hair
- The evaluation and management of hirsutism*1
- Randomized, double‐blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair
- Methods in hair research: how to objectively distinguish between anagen and catagen in human hair follicle organ culture
- A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women
- Medical treatment of hirsutism
- Guidance for the management of hirsutism